Search
Dr Reddy's Laboratories Ltd
RDYAdd to Watchlist
13.290USD
+0.155+1.18%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
11.07BMarket Cap
22.80P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Dr Reddy's Laboratories Ltd is 6.50, ranking 128 out of 157 in the Pharmaceuticals industry. The average price target is 14.53, with a high of 18.82 and a low of 11.90.
Analyst Rating
Based on
4
analysts
Hold
Current Rating
15.120
Target Price
+14.98%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Dr Reddy's Laboratories Ltd
RDY
4
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Dr Reddy's Laboratories Ltd's expected revenue for the next quarter?
Dr Reddy's Laboratories Ltd's expected revenue is 865.88M.
What is Dr Reddy's Laboratories Ltd's price target?
Analysts forecast that Dr Reddy's Laboratories Ltd's price target is USD 14.53, with the highest forecast at USD 18.82 and the lowest forecast at USD 11.90.
How have Dr Reddy's Laboratories LtdRDY's recent earnings per share performed?
The market expectation was USD 0.03, while Dr Reddy's Laboratories LtdRDY's earnings per share (EPS) for the previous quarter was USD 0.16. EPS for the next quarter is expected at USD 0.09.
What is the analyst rating for Dr Reddy's Laboratories Ltd?
Based on the ratings of Dr Reddy's Laboratories Ltd's stock from 4 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.
